MindWalk Holdings Corp. (IPA)

Overview

ImmunoPrecise Antibodies Ltd. is a pioneering biotherapeutic research and technology company with global operations, based in Victoria, Canada. Since its inception in 1983, the company has been at the forefront of addressing complex challenges in the development of biotherapeutics. Catering to a diverse clientele that spans across the globe, ImmunoPrecise Antibodies Ltd. showcases a broad spectrum of cutting-edge services and technologies designed to support the discovery, development, and refinement of novel antibody-based therapies. By deploying a comprehensive suite of tools and methodologies, the company stands as a beacon of innovation in the rapidly evolving biotherapeutic sector.

Products and Services

• NonaVac DNA

  Facilitates the generation of biotherapeutics targeting complex protein classes such as GPCRs and ion channels, addressing a critical need in the field.

• Rapid Prime

  Designed to produce positive monoclonal antibodies efficiently, Rapid Prime is pivotal for generating anti-idiotypic antibodies and targeting conformational epitopes.

• Syngeneic Cell Line

  Provides a robust platform for immunization and screening processes, enhancing the discovery potential for novel antibodies.

• Peptide Production

  An essential service supporting subsequent antibody discovery campaigns through high-quality peptide synthesis.

• B cell select platform

  Allows for in-depth analysis of animal antibody repertoires, enabling direct selection of desired antibodies from B cells in rabbits and chickens.

• Single Step Hybridoma

  A streamlined process for growing mouse and rat hybridomas in a semi-solid media, facilitating the development of monoclonal antibodies.

• DeepDisplay

  Combines transgenic animal platforms with custom IPA phage display for enhanced antibody selection.

• Phage Display

  Custom immune library creation across multiple species, offering a versatile approach to antibody discovery.

• Car Development

  Provides adaptable antibodies incorporating functional data early in the screening process, optimizing CAR-T cell therapies.

• Silico Developability

  An advanced profiling toolkit for assessing lead antibody candidates, aiding in the selection of viable therapeutic options.

• In Vitro Analytical Tools

  Extensive analytical capabilities for studying critical quality attributes of antibodies, crucial for therapeutic development.

• LucinaTech

  Offers antibody humanization services focusing on identifying essential residues, supporting the development of therapeutically relevant antibodies.

• Antibody Affinity Maturation

  Targets the enhancement of antibody affinity for therapeutic and diagnostic applications, improving efficacy and specificity.

• Antibody Chimerization

  Facilitates the cloning and production of variable antibody domains, crucial for creating chimeric antibodies for research and therapy.

• Eurofins Preclinical Services

  Provides comprehensive preclinical testing services through partnership with Eurofins, ensuring the safety and efficacy of biotherapeutic products.

• Hybrid Service Model

  A unique service model aimed at reducing time and risk in biotherapeutic development through the integration of custom technologies and applications.

• Breadth and Depth

  Accelerates the development of assays, screening cascades, drug candidate validation, and the realization of new biotherapeutic concepts.